Oncolytics Biotech Inc. (NASDAQ: ONCY) completed its domestication from the Province of Alberta, Canada, to the State of Nevada on March 31 2026, making the company a U.S. domestic issuer and eliminating its status as a foreign private issuer under U.S. securities laws.
Shareholder approval for the domestication was granted on January 15 2026, and the company first continued its existence from Alberta to British Columbia on March 17 2026 before the final transition to Nevada. The new CUSIP number is 68237V103 and the ISIN is US68237V1035, effective April 1 2026.
Oncolytics will keep its Calgary office while relocating its headquarters to San Diego, California. The move is intended to streamline regulatory compliance, improve operational efficiency, and enhance access to U.S. capital markets, with Nevada chosen for its favorable corporate legal environment.
"We are encouraged by the potential benefits that Nevada's corporate legal environment presents to biotech companies, especially given our focus on operational efficiency across the company. As we no longer qualified as a “foreign private issuer” under applicable U.S. securities laws, it made sense to overhaul our corporate structure and change Oncolytics' jurisdiction of incorporation to reflect its status as a U.S. domestic issuer," said CEO Jared Kelly.
"Our decision to seek to change the Company's jurisdiction of incorporation to the State of Nevada reflects where Oncolytics is today and where we are headed. We are a U.S.-focused oncology company with U.S.-based leadership, operations, and investors. This move simplifies our structure, improves capital markets access, and positions us more effectively for future strategic opportunities, including partnerships and potential M&A activity. We believe Nevada offers a compelling long‑term home for biotech companies like ours," added Kelly.
The domestication may reduce stockholder rights and discourage takeover attempts due to Nevada’s governance provisions, but it also facilitates a new 2026 Incentive Award Plan and may enable a Form S‑3 shelf offering of up to $250 million in securities.
Oncolytics’ core business remains the development of pelareorep, an investigational immunotherapeutic agent that has received FDA Fast Track designation for colorectal and pancreatic cancer. The company is advancing pelareorep in combination with chemotherapy and checkpoint inhibitors, positioning it for future clinical milestones.
The transition to Nevada aligns the company’s corporate structure with its U.S.-centric operations and investor base, potentially improving capital‑raising efficiency and strategic flexibility for partnerships and M&A.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.